NONALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NONALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise against fatty liver disease in Mid-Stage trial
Disease control OngoingThis study tests whether the drug miricorilant can safely reduce liver fat in adults with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease. About 175 participants will receive either the drug or a placebo, and doctors will measure liver fat changes using MRI. Th…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 26, 2026 08:16 UTC
-
New drug aimed at reversing fatty liver disease shows promise in trial
Disease control TerminatedThis study tests a drug called Aramchol in people with nonalcoholic steatohepatitis (NASH), a serious liver condition linked to obesity and diabetes. The goal is to see if Aramchol can reduce liver scarring and improve liver health. About 150 adults with confirmed NASH and modera…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE3 • Sponsor: Galmed Research and Development, Ltd. • Aim: Disease control
Last updated May 26, 2026 08:09 UTC